SAN FRANCISCO, Jan. 28 (GenomeWeb News) - Danish drug-discovery firm BioImage and Evotec Technologies have co-validated BioImage's cell-based assay technology on Evotec's line of high-content screening instruments, the companies said this week.
Interviewed at Cambridge Healthtech Institutes' High-Content Analysis conference, held here this week, the firms said they have validated BioImage's Redistribution fluorescent assays for protein translocation on Evotec's Opera confocal-based high-content screening instrument.
Company officials at the meeting said BioImage has now made available full application notes for researchers wishing to apply Redistribution assays on an Opera system. This is the third major high-content instrument platform on which BioImage has validated its assays. The other two platforms are GE Healthcare's IN Cell Analyzer and Cellomics' ArrayScan.
The agreement, which has not been formally announced by either company, caps a busy week for BioImage. As reported last week by Inside Bioassays, a GenomeWeb News sister publication, BioImage was expected to announce an agreement to license Redistribution to an undisclosed top-10 pharmaceutical company. This week, BioImage revealed that the company is Boehringer Ingelheim, which has been granted full use of the Redistribution assays in its drug-discovery programs.
In addition, earlier this week BioImage and German biotech RNAx said that they had penned a partnership to provide RNAx's RNAi-knockdown technology as a complement the Redistribution assays for drug-discovery and other cell biology applications.
Financial terms of the deals were not disclosed.